New immunotherapy cocktail takes on pancreatic cancer in phase 2 trial

NCT ID NCT04390399

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study tests whether adding an immunotherapy combination (aldoxorubicin, N-803, and PD-L1 t-haNK) to standard chemotherapy helps people with advanced pancreatic cancer live longer without their cancer growing. About 328 adults with locally advanced or metastatic pancreatic cancer are taking part. The goal is to see if the new combo improves outcomes like tumor shrinkage and quality of life compared to chemotherapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Astera Cancer Care

    East Brunswick, New Jersey, 08816, United States

  • Avera Cancer Institute

    Sioux Falls, South Dakota, 57105, United States

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California, 90245, United States

  • Hoag memorial Presbyterian Hospital

    Newport Beach, California, 92663, United States

Conditions

Explore the condition pages connected to this study.